Vertex Pharmaceuticals said the Board of Directors approved on March 27, 2026 the 2026 Stock and Option Plan, which replaces the 2013 Stock and Option Plan, subject to shareholder approval, which was received at the annual meeting of shareholders held on May 13, 2026.

1. 01

   Vertex Pharmaceuticals said the Board of Directors approved on March 27, 2026 the 2026 Stock and Option Plan, which replaces the 2013 Stock and Option Plan, subject to shareholder approval, which was received at the annual meeting of shareholders held on May 13, 2026.

2. 02

   The company said shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani and Michel Lagarde, among others, to serve as directors until the annual meeting of shareholders to be held in 2027 at the annual meeting held on May 13, 2026.

3. 03

   Vertex Pharmaceuticals said a shareholder proposal regarding shareholder right to act by written consent was approved with 126,892,696 votes in favor, 95,756,148 votes against and 348,792 abstentions.

4. 04

   The company said the 2026 Stock and Option Plan was approved with 216,097,268 votes in favor and 6,523,460 votes against, and Ernst & Young LLP was approved as the independent registered public accounting firm for the year ending December 31, 2026.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.